Main Article Content
The bioequivalence of two brands of 7.5 mg meloxicam were demonstrated in healthy volunteers after a single oral dose in a randomized 2-period crossover study. The reference and the test formulation were administered to fasted male volunteers, thereafter, the blood samples were collected at specific time interval from 0-96 h. The washout period was 2 weeks. The plasma meloxicam concentrations were determined by HPLC. The pharmacokinetic parameters obtained after non-compartmental analysis were statistically evaluated for bioequivalence using ANOV A. RESULT; The median Tmax (h) of the two products were similar ( 4.5 VS 4.0), however, the range of Tmax (h) for the reference product (2 .0-10.0) was more variable than that of the test (4.0-10.0). Bioequivalence analysis showed that the Cmax and the AUCo-∞ did not differ significantly. The point estimator (90%CI) for the ratio Test/Reference of log transformed data of the AUCo-∞ and Cmax were 0.97 (0.90-1.06) and 0.95 (0.84-1.08), respectively. These values were within the bioequivalence range of 0.80-1.25, thus our study demonstrated the bioequivalence of the test and the reference preparations.
Upon acceptance of an article, the Pharmacological and Therapeutic Society of Thailand will have exclusive right to publish and distribute the article in all forms and media and grant rights to others. Authors have rights to use and share their own published articles.